Thrombin inhibition and intracoronary thrombus formation: Effect of polyethylene glycol-coupled hirudin in the stenosed, locally injured canine coronary artery

Coronary Artery Disease

Volumn 9, Issue 1, 1998, Pages 35-42

  Rübsamen, Klaus ^a   Kirchengast, Michael ^a  

^a Knoll AG   (Germany)

Author keywords

Anticoagulants; Coronary artery stenosis; PEG hirudin; Thrombin inhibitors; Thrombosis

Indexed keywords

HIRUDIN; LU 87981; MACROGOL; THROMBIN; THROMBIN INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; CORONARY ARTERY OBSTRUCTION; CORONARY ARTERY THROMBOSIS; DOG; LEFT ANTERIOR DESCENDING CORONARY ARTERY; NONHUMAN; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; THROMBOCYTE FUNCTION; THROMBOGENESIS;

EID: 0031894671     PISSN: 09546928     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019501-199809010-00006     Document Type: Article

References (42)

1. Theroux P, Ouimet H, McCans J, Latour J, Joly P, Levy G, et al. Aspirin, heparin, or both to treat acute unstable angina. N Engl J Med 1988; 319:1105-1111.
2. Heras M, Chesebro JH, Webster MWI, Mruk JS, Grill DE, Penny WJ, et al. Hirudin, heparin, and placebo during deep arterial injury in the pig. The in vivo role of thrombin in platelet-mediated thrombosis. Circulation 1990; 82:1476-1484.
3. Heras M, Chesebro JH, Penny WJ, Bailey KR, Badimon L, Fuster V. Effects of thrombin inhibition on the development of acute platelet-thrombus deposition during angioplasty in pigs. Circulation 1998; 79:657-665.
4. Lam JYT, Chesebro JH, Steele PM, Heras M, Webster MWI, Badimon L, et al. Antithrombotic therapy for deep arterial injury by angioplasty. Efficacy of common platelet inhibition compared with thrombin inhibition in pigs. Circulation 1991; 84:814-820.
5. Kelly AB, Marzec UM, Krupski W, Bass A, Cadroy Y, Hanson SR, et al. Hirudin interruption of heparin-resistant arterial thrombus formation in baboons. Blood 1991; 77:1006-1012.
6. Krupski WC, Bass A, Kelly AB, Marzec UM, Hanson SR, Harker LA. Heparin-resistant thrombus formation by endovascular stents in baboons. Circulation 1990; 81:570-577.
7. Jackson CV, Wilson HC, Growe VG, Shuman RT, Gesellchen PD. Reversible tripeptide thrombin inhibitors as adjunctive agents to coronary thrombolysis: a comparison with heparin in a canine model of coronary artery thrombosis. J Cardiovasc Pharmacol 1993; 21:587-594.
8. Yasuda T, Gold HK, Yaoita H, Leinbach RC, Guerrero JL, Jang I-K, et al. Comparative effects of aspirin, a synthetic thrombin inhibitor and a monoclonal antiplatelel glycoprotein IIb/IIIa antibody on coronary artery reperfusion, reocclusion and bleeding with recombinant tissue-type plasminogen activator in a canine preparation. J Am Coll Cardiol 1990; 16:714-722.
9. Weitz JI, Hudoba M, Massel D, Maraganore J, Hirsh J. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest 1990; 88:385-391.
10. Topol EJ, Fuster V, Harrington RA, Califf RM, Kleiman NS, Kereiakes DJ, et al. Recombinant hirudin for unstable angina pectoris. A multicenter, randomized angiographic trial. Circulation 1994; 89:1557-1566.
11. Lidon R-M, Theroux P, Juneau M, Adelman B, Maraganore J. Initial experience with a direct antithrombin, hirulog, in unstable angina: anticoagulant, antithrombotic and clinical effects. Circulation 1993; 88:1495-1501.
12. Topol EJ, Bonan R, Jewitt D, Sigwart U, Kakkar W, Rothman M, et al. Use of a direct antithrombin, hirulog, in place of heparin during coronary angiogioplasty. Circulation 1993; 87:1622-1629.
13. van den Bos AA, Deckers JW, Heyndrickx GR, Laarman G-J, Suryapranata H, Zijlstra F, et al. Safety and efficacy of recombinant hirudin (CGP 39393) versus heparin in patients with stable angina undergoing coronary angioplasty. Circulation 1993; 88:2058-2066.
14. Zoldhelyi P, Webster MWI, Fuster V, Grill DE, Gaspar D, Edwards SJ, et al. Recombinant hirudin in patients with chronic, stable coronary artery disease. Safety, half-life, and effect on coagulation parameters. Circulation 1993; 88:2015-2022.
15. Lidon R-M, Theroux P, Lesperance J, Adelman B, Bonan R, Duval D, et al. A pilot, early angiographic patency study using a direct thrombin inhibitor as adjunctive therapy to streptokinase in acute myocardial infarction. Circulation 1994; 89:1567-1572.
16. Cannon CP, McCabe CH, Henry TD, Schweiger MJ, Gibson RS, Mueller HS. A pilot study of recombinant desulfatohirudin compared with heparin in conjunction with tissue-type plasminogen activator factor and aspirin for acute myocardial infarction: results of the thrombolysis in myocardial infarction (TIMI) 5 trial. J Am Coll Cardiol 1994; 23:993-1003.
17. Gold HK, Torres FW, Garabedian HD, Werner W, Jang IK, Khan A, et al. Evidence for a rebound phenomenon after cessation of a 4-hour infusion of a specific thrombin inhibitor in patients with unstable angina pectoris. J Am Coll Cardiol 1993; 21:1039-1047.
18. Theroux P, Waters D, Lam J, Juneau M, McCans J. Reactivation of unstable angina after the discontinuation of heparin. N Engl J Med 1992; 327:141-145.
19. Rapold HJ, de Bono D, Arnold AER, Arnout J, De Cock F, Collen D, et al. Plasma fibrinopeptide A levels in patients with acute myocardial infarction treated with alteplase. Correlation with concomitant heparin, coronary artery patency, and recurrent ischemia. Circulation 1992; 85:928-934.
20. Szczeklik A, Dropinski J, Radwan J, Krzanowski M. Persistent generation of thrombin after acute myocardial infarction. Arterioscl Thromb 1992; 12:548-553.
21. Merlini PA, Bauer KA, Oltrona L, Ardissino D, Spinola A, Cattaneo M, et al. Thrombin generation and activity during thrombolysis and concomitant heparin therapy in patients with acute myocardial infarction. J Am Coll Cardiol 1995; 25:203-209.
22. Marmur JD, Merlini PA, Sharma SK, Khaghan N, Torre SR, Israel DH, et al. Thrombin generation in human coronary arteries after percutaneous transluminal balloon angioplasty. J Am Coll Cardiol 1994; 24:1484-1491.
23. Zoldhelyi P, Bichler J, Owen WG, Grill DE, Fuster V, Mruk JS, et al. Persistent thrombin generation in humans during specific thrombin inhibition with hirudin. Circulation 1994; 90:2671-2678.
24. ichler J, Fichtl B, Siebeck M, Fritz H. Phamnacokinetics and pharmacodynamics of hirudin in man after single subcutaneous and intravenous bolus administration. Arzneimittelforsch 1988; 38:704-710.
25. Verstraete M, Nurmohamed M, Kienast J, Siebeck M, Silling-Engelhardt G, Büller H, et al. Biologic effects of recombinant hirudin (CGP 39393) in human volunteers. J Am Coll Cardiol 1993; 22:1080-1088.
26. Fox I, Dawson A, Loynds P, Eisner J, Findlen K, Levin E, et al. Anticoagulant activity of hirulog™, a direct thrombin inhibitor, in humans. Thromb Haemost 1993; 69:157-163.
27. Merlini PA, Bauer KA, Oltrona L, Ardissino D, Cattaneo M, Belli C, et al. Persistent activation of coagulation mechanism in unstable angina and myocardial infarction. Circulation 1994; 90:61-68.
28. Rübsamen K, Hornberger W, Laux V, Schwarz M, Schweden J. Antithrombotic efficacy of the polyethyleneglycol-coupled hirudin mutein LU 57291 in experimentally induced venous and arterial thrombosis [Abstract]. Thromb Haemost 1993; 69:2717.
29. Esslinger H-U, Haas S, Maurer R, Lassmann A, Dübbers K, Müller-Peltzer H. Pharmacodynamic and safety results of PEG-hirudin in healthy volunteers. Thromb Haemost 1997; 77:911-919.
30. Folts JD. An in vivo model of experimental arterial stenosis, intimai damage, and periodic thrombosis. Circulation 1991; 83 (suppl IV):IV-3-IV-14.
31. 2-receptor antagonist nexopamil (LU 49938) of intracoronary thrombus formation in a canine model of arterial stenosis and intimal damage. J Cardiovasc Pharmacol 1993; 22:687-694.
32. Folts JD, Crowell EB, Rowe GG. Platelet aggregation in partially obstructed vessels and its elimination with aspirin. Circulation 1976; 54:365-370.
33. Brassard JA, Meyers KM. Evaluation of the buccal bleeding time and platelet glass bead retention as assays of hemostasis in the dog: the effects of acetylsalicylic acid, warfarin and von Willebrand factor deficiency. Thromb Haemost 1991; 65:191-195.
34. Spannagl M, Bichler J, Birg A, Lill H, Schramm W. Development of a chromogenic substrate assay for the determination of hirudin in plasma. Blood Coagul Fibrinolysis 1991; 2:121-127.
35. Kurfürst M, Rübsamen K, Schmied B, Koerwer W, Schweden J, Hoeffken HW. Hirudinpolyalkylenglykolkonjugate. Patent No. PCT/EP 90/01998.
36. Haas S, Esslinger H-U, Stemberger A, Baumgartner M, Müller-Peltzer H, Blümel G. Placebo-controlled trial on the anticoagulant effects of PEG-hirudin (LU 57291) as intravenous infusion in healthy volunteers [Abstract]. Ann Haematol 1995; 70 (suppl):A 45.
37. Haskel EJ, Prager NA, Sobel BE, Abendschein DR. Relative efficacy of antithrombin compared with antiplatelet agents in accelerating coronary thrombolysis and preventing early reocclusion. Circulation 1991; 83:1048-1056.
38. Rigel DF, Olson RW, Lappe RW. Comparison of hirudin and heparin as adjuncts to streptokinase thrombolysis in a canine model of coronary thrombosis. Circ Res 1993; 72:1091-1102.
39. Neuhaus K-L, Essen RV, Tebbe U, Jessel A, Heinrichs H, Mäurer W, et al. Safety observations from the pilot phase of the randomized r-hirudin for improvement of thrombolysis (HIT-III) study. Circulation 1994; 90:1638-1642.
40. Antmann EM. Hirudin in acute myocardial infarction. Safety report from the thrombolysis and thrombin inhibition in myocardial infarction (TIMII) 9A trial. Circulation 1994; 90:1624-1630.
41. Kaplan AV, Leung LLK, Leung WH, Grant GW, McDougall R, Fischell TA. Roles of thrombin and platelet membrane glycoprotein IIb/IIIa in platelet-subendothelial deposition after angioplasty in an ex vivo whole artery model. Circulation 1991; 84:1279-1288.
42. Alig L, Edenhofer A, Hadvary P, Hürzeler M, Knopp D, Müller M, et al. Low molecular weight, non-peptide fibrinogen receptor antagonists. J Med Chem 1992; 35:4393-4407.